Eroms-DT EDTA Injection is a sterile, intravenous formulation combining Meropenem 1000 mg and Sulbactam 1000 mg, designed for the treatment of severe bacterial infections. Meropenem, a broad-spectrum carbapenem antibiotic, exerts bactericidal activity by inhibiting bacterial cell wall synthesis, effective against a wide range of Gram-positive, Gram-negative, and anaerobic pathogens. Sulbactam, a beta-lactamase inhibitor, enhances the efficacy of Meropenem by preventing the degradation of the antibiotic by beta-lactamase-producing bacteria, thereby extending its spectrum of activity. The inclusion of EDTA serves as a chelating agent, potentially disrupting bacterial biofilms and enhancing antimicrobial penetration. Eroms-DT EDTA Injection is indicated for complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired pneumonia, and other severe infections caused by susceptible organisms. The combination is particularly useful in treating infections caused by multidrug-resistant strains. Dosage and administration should be guided by the severity of infection, renal function, and susceptibility patterns. Adverse effects may include hypersensitivity reactions, gastrointestinal disturbances, and potential alterations in hematologic parameters. Caution is advised in patients with known hypersensitivity to carbapenems, beta-lactams, or EDTA. This combination therapy offers a potent option in the management of complex bacterial infections requiring broad-spectrum coverage and beta-lactamase inhibition.